Andy Sassine - 15 Aug 2025 Form 4/A - Amendment Insider Report for Arcturus Therapeutics Holdings Inc. (ARCT)

Reporting relationship: Chief Financial Officer, Director
Issuer ticker: ARCT
Reported as of: 15 Aug 2025
Net transaction value: +$20,499
SEC form: 4/A - Amendment
Accepted by SEC: 20 Aug 2025, 16:01:44 UTC
Original report date: 19 Aug 2025
Prior SEC filing: 17 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Ilan Katz, attorney-in-fact

Key filing fact

Andy Sassine filed Form 4/A - Amendment for Arcturus Therapeutics Holdings Inc. (ARCT) on 20 Aug 2025.

Key facts

This page summarizes Andy Sassine's Form 4/A - Amendment filing for Arcturus Therapeutics Holdings Inc. (ARCT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 Aug 2025, 16:01.

Change

Previous filing in this sequence was filed on 17 Jul 2025.
Current net transaction value: +$20,499.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001515322 Primary reporting owner

SASSINE ANDY

Relationship: Chief Financial Officer, Director
Address: C/O ARCTURUS THERAPEUTICS HOLDINGS INC., 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO
Signature: /s/ Ilan Katz, attorney-in-fact
Signature date: 20 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARCT transaction

Common Stock

Purchase

Transaction value: $20,499
Shares: +1,238
Change %: +0.56%
Price: $16.56
Shares after: 221,764
Date: 15 Aug 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The purchase reported on this Form 4 was effected by the Reporting Person pursuant to the Arcturus Therapeutics Holdings Inc. 2020 Employee Stock Purchase Plan (the "ESPP").

Footnote F2

In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 15, 2025.